TY - JOUR
T1 - Estrogen therapy and thrombotic risk
AU - Miller, Virginia M.
AU - Jayachandran, Muthuvel
AU - Heit, John A.
AU - Owen, Whyte G.
PY - 2006/9
Y1 - 2006/9
N2 - Post-menopausal hormone therapy increases the risk for venous thrombosis, and possibly myocardial infarction (MI) and ischemic stroke. However, most women using hormone therapy do not suffer thrombosis, and to date our ability to identify women at risk is limited. Thrombosis, arterial or venous, has 2 requisites: a vascular anomaly and a response of the hemostasis system to the anomaly. Consequently, experimental approaches to understand the pathophysiology of thrombosis require definition of vascular anatomy and function as well as characteristics of the blood within the context of genetic background, lifestyle choices and environmental exposures, which influence gene expression. Defining interactions among factors that affect individual propensity to thrombosis will allow physicians to better identify at-risk individuals, for example a woman contemplating estrogen therapy for symptoms of menopause, and prevent adverse thrombotic events.
AB - Post-menopausal hormone therapy increases the risk for venous thrombosis, and possibly myocardial infarction (MI) and ischemic stroke. However, most women using hormone therapy do not suffer thrombosis, and to date our ability to identify women at risk is limited. Thrombosis, arterial or venous, has 2 requisites: a vascular anomaly and a response of the hemostasis system to the anomaly. Consequently, experimental approaches to understand the pathophysiology of thrombosis require definition of vascular anatomy and function as well as characteristics of the blood within the context of genetic background, lifestyle choices and environmental exposures, which influence gene expression. Defining interactions among factors that affect individual propensity to thrombosis will allow physicians to better identify at-risk individuals, for example a woman contemplating estrogen therapy for symptoms of menopause, and prevent adverse thrombotic events.
KW - 17β-estradiol
KW - C-reactive protein
KW - KEEPS trial
KW - Platelets
KW - Venous thrombosis
KW - Women's Health Initiative
UR - http://www.scopus.com/inward/record.url?scp=33746363509&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33746363509&partnerID=8YFLogxK
U2 - 10.1016/j.pharmthera.2006.01.001
DO - 10.1016/j.pharmthera.2006.01.001
M3 - Review article
C2 - 16473411
AN - SCOPUS:33746363509
VL - 111
SP - 792
EP - 807
JO - Pharmacology and Therapeutics, Part A: Chemotherapy, Toxicology and
JF - Pharmacology and Therapeutics, Part A: Chemotherapy, Toxicology and
SN - 0163-7258
IS - 3
ER -